Summary of COVID-19 losmapimod studies

1. Ziegler et al., A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)

52 patient losmapimod late treatment RCT: 18% higher progression (p=0.54) and 14% worse recovery (p=0.64).
RCT 52 hospitalized COVID-19 patients showing no significant differences with losmapimod treatment.
Mar 2021, NCT04511819, https://clinicaltrials.gov/study/NCT04511819, https://c19p.org/ziegler